A paradigm shift in psoriasis treatment: deucravacitinib’s significance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A paradigm shift in psoriasis treatment: deucravacitinib’s significance

Published:2023-11-07 Issue:12 Volume:85 Page:5866-5868
ISSN:2049-0801
Container-title:Annals of Medicine & Surgery
language:en
Short-container-title:

Author:

Ishtiaque Galib M. Abrar¹,Supti Fatema A.¹,Amin Ruhul²,Emran Talha B.³

Affiliation:

1. Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka, Bangladesh

2. Faculty of Pharmaceutical Science, Assam Down Town University, Panikhaiti, Guwahati, Assam, India

3. Department of Pharmacy, BGC Trust University Bangladesh, Chittagong, Bangladesh

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,Surgery

Reference14 articles.

1. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis;Catlett;J Allergy Clin Immunol,2022

2. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors;Chimalakonda;Dermatol Ther (Heidelb),2021

3. A natural mutation in the TYK2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity;Shaw;Proc Natl Acad Sci USA,2003

4. First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2;Catlett;Clin Transl Sci,2023

5. Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors;Martin;Dermatol Ther (Heidelb),2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP